SABCS 2020 | monarchE: abemaciclib and adjuvant endocrine therapy for high-risk HR+ early breast cancer

Priya Rastogi, MD, University of Pittsburgh, Pittsburgh, PA, discusses the primary outcome analysis of the monarchE study, (NCT03155997), evaluating abemaciclib, a CDK46 inhibitor in combination with adjuvant endocrine therapy for high-risk early breast cancer. The results of this study suggest that the abemaciclib treatment arm showed improved outcomes in patients with hormone-receptor-positive breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).